

## Curriculum Vitae

**Frauke Stanke** PD Dr. rer. nat.  
d.o.b. March 12th, 1970, in Essen, Germany

### University Education

2012 Habilitation Molecular Human Genetics, MHH  
2000 Doctorate Biochemistry (Dr. rer. nat.), MHH  
1989-1994 Studies of biochemistry, University of Hannover and Hannover Medical School (MHH)

### Scientific Career

since 2022: board member of the Forschungsgemeinschaft Mukoviszidose e.V. (FGM)  
[<https://www.muko.info/ueber-den-verein/arbeitskreise/forschungsgemeinschaft-mukoviszidose-fgm>]  
since 2022: principle investigator within the Center for Infection Biology (Zentrum für Infektionsbiologie, ZIB) of the Hannover Medical School, Germany  
[<https://www.mhh.de/hbrs/zib>]  
since 2020: spokesperson for the working group “Medical Bioinformatics and Systems Medicine” (BioSysMed) of the TMF e.V [https://www.tmf-ev.de/Arbeitsgruppen\_Foren/AGBioinfSysmed.aspx]  
since 2012: principal investigator within the German Center for Lung Research (Deutsches Zentrum für Lungenforschung DZL), BREATH Faculty, disease area cystic fibrosis  
[<https://www.breath-hannover.de/>]  
since 2007: delegate for the „Technologie- und Methodenplattform für die vernetzte medizinische Forschung e.V.“ (TMF e.V.) for the Mukoviszidose Institut gGmbH [https://www.tmf-ev.de/home.aspx]  
since 2007: member of the expert committee Ecorn-CF (European Centres of Reference Network for Cystic Fibrosis) funded 2007-2010 by the European Union [https://ecorn-cf.eu/index.php?id=60]

### Supplementary Career Information

Personal statement: Frauke Stanke, née Mekus, married, one child (02/2010)  
since 04/2011: tenure as a senior research scientist realized as half-time position (50%)  
10/2009-04/2011: maternity protection leave and parental leave

### Awards and Honors

2013 Adolf-Windorfer-Preis awarded by the Mukoviszidose e.V.

### Citation Record

Total Citations: 1317; h-index 21 (Clarivate Web of Science March 9<sup>th</sup> 2026)

### Top-10 selected Publications

Uden A, Dunsche I, Janciauskiene S, Gräber S, Feng L, Tamm S, Hedtfeld S, Stege G, Jahn K, Kontsendorn J, Alfeis N, Kühbandner I, Minso R, Dopfer C, Griese M, Sommerburg O, Ringshausen FC, Nährlich L, Hansen G, Welte T, Braubach P, Mall MA, Tümmler B, Dittrich AM, **Stanke F**, CF teams from the European CF Twin and Sibling Study. Genotype and transcript processing of the tumour necrosis factor receptor TNFRSF1A in epithelial cells: implications for survival in cystic fibrosis. *EBioMedicine*. 2025;118:105848. doi:[10.1016/j.ebiom.2025.105848](https://doi.org/10.1016/j.ebiom.2025.105848)

**Stanke F**, Pallenberg ST, Tamm S, Hedtfeld S, Eichhorn EM, Minso R, Hansen G, Welte T, Sauer-Heilborn A, Ringshausen FC, Junge S, Tümmler B, Dittrich AM. Changes in cystic fibrosis transmembrane

conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy. *Front Pharmacol.* 2023;14:1114584. doi:[10.3389/fphar.2023.1114584](https://doi.org/10.3389/fphar.2023.1114584)

Dunsche I, Raddatz EL, Ismer H, Hedtfeld S, Tamm S, Moser S, Kontsendorn J, Tümmler B, Janciauskiene S, Dittrich AM, **Stanke F**. Analysis of CF patient survival confirms STAT3 as a CF-modifying gene with changing impact over time. *Hum Mol Genet.* 2023;32(4):543-550. doi:[10.1093/hmg/ddac221](https://doi.org/10.1093/hmg/ddac221)

Vinhoven L, **Stanke F**, Hafkemeyer S, Nietert MM. Complementary Dual Approach for In Silico Target Identification of Potential Pharmaceutical Compounds in Cystic Fibrosis. *Int J Mol Sci.* 2022;23(20). doi:[10.3390/ijms232012351](https://doi.org/10.3390/ijms232012351)

Niertert MM, Vinhoven L, Auer F, Hafkemeyer S, **Stanke F**. Comprehensive Analysis of Chemical Structures That Have Been Tested as CFTR Activating Substances in a Publicly Available Database CandActCFTR. *Front Pharmacol.* 2021;12:689205. doi:[10.3389/fphar.2021.689205](https://doi.org/10.3389/fphar.2021.689205)

Schamschula E, Hagmann W, Assenov Y, Hedtfeld S, Farag AK, Roesner LM, Wiehlmann L, **Stanke F**, Fischer S, Risch A, Tümmler B. Immunotyping of clinically divergent p.Phe508del homozygous monozygous cystic fibrosis twins. *J Cyst Fibros.* 2021;20(1):149-153. doi:[10.1016/j.jcf.2020.06.009](https://doi.org/10.1016/j.jcf.2020.06.009)

Becker T, Pich A, Tamm S, Hedtfeld S, Ibrahim M, Altmüller J, Dalibor N, Toliat MR, Janciauskiene S, Tümmler B, **Stanke F**. Genetic information from discordant sibling pairs points to ESRP2 as a candidate trans-acting regulator of the CF modifier gene SCNN1B. *Sci Rep.* 2020;10(1):22447. doi:[10.1038/s41598-020-79804-y](https://doi.org/10.1038/s41598-020-79804-y)

**Stanke F**, Hector A, Hedtfeld S, Hartl D, Griese M, Tümmler B, Mall MA. An informative intragenic microsatellite marker suggests the IL-1 receptor as a genetic modifier in cystic fibrosis. *Eur Respir J.* 2017;50(6):1700426. doi:[10.1183/13993003.00426-2017](https://doi.org/10.1183/13993003.00426-2017)

Awah CU, Tamm S, Hedtfeld S, Steinemann D, Tümmler B, Tsiavaliaris G, **Stanke F**. Mechanism of allele specific assembly and disruption of master regulator transcription factor complexes of NF-KBp50, NF-KBp65 and HIF1a on a non-coding FAS SNP. *Biochim Biophys Acta.* 2016;1859(11):1411-1428. doi:[10.1016/j.bbagr.2016.09.002](https://doi.org/10.1016/j.bbagr.2016.09.002)

**Stanke F**, Becker T, Kumar V, Hedtfeld S, Becker C, Cuppens H, Tamm S, Yarden J, Laabs U, Siebert B, Fernandez L, Macek MJ, Radojkovic D, Ballmann M, Greipel J, Cassiman JJ, Wienker TF, Tümmler B. Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia. *J Med Genet.* 2011;48(1):24-31. doi:[10.1136/jmg.2010.080937](https://doi.org/10.1136/jmg.2010.080937)